Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED)

NCT07155668 is registered in ClinicalTrials.gov with Viridian Therapeutics, Inc. as lead sponsor.

NCT NCT07155668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07155668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED)
Lead sponsor
Viridian Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2025
Completion date
May 28, 2026
Enrollment
87 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease